Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses.
This is one of the largest PRCTs of colloid vs. colloid to date. It forms the basis of the new European dose limit for HES 130/0.4 at 50 mL/kg. Trials […]
The in vitro effects of crystalloids and colloids on coagulation.
Worth a close look for those with a specialist interest in this area. Adds to a fast growing body of literature on the various effects of i.v. solutions on coagulation […]
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
This is a case report of two female patients with severe vaginal bleeding following previous treatment of gynecological malignancies and no pre-existing coagulation factor deficiency. Bleeding was controlled with two […]
Treatment of critical bleeding in the future intensive care unit. [Editorial]
Uncontrolled bleeding remains a major problem in intensive care and emergency medicine which still requires effective and innovative treatment options. This editorial highlights that there is growing evidence on the […]
Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta.
This is another case report on the efficacy of Novoseven in controlling severe bleeding in cardiac surgery. Post-operative bleeding continued in spite of the use of blood products and aprotinin […]
Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report.
This is an interesting case report on the use of rFVIIa in treating uncontrollable surgical bleeding in a patient not known to have a pre-existing coagulopathy. The patient had a […]
Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: A pilot study.
This is an interesting work showing the efficacy of rFVIIa in controlling post traumatic hemorrhage in an animal model, especially after the publication of several case reports of the effective […]
Effectiveness of combined blood conservation measures in thoracic aortic operations with deep hypothermic circulatory arrest.
Note: See also the useful invited commentary by John A. Elefteriades on pages 743-4. – F. Regan and M. Contreras.
Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.
Etiology of bleeding in cirrhotic patients during surgery is multifactorial, and its management includes several measures such as replacement of coagulation factors and platelets as well as the use of […]
Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A.
This is a very interesting article which casts new light on the mechanism of hemostasis of rFVIIa in hemophiliac patients with inhibitors to factor VIII. rFVIIa is known to exert […]
Use of recombinant factor VII in hepatology.
This article starts with a general overview on mechanism of action, uses and safety of rFVIIa as well as the hemostatic disorders which are associated with liver disease. It states […]
Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect.
This study supports the hypothesis that aprotinin is an anticoagulant which prolongs the aPTT and has no or marginal risks of thromboembolic complications. – Wulf Dietrich.
Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.
This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin time and effective control of bleeding esophageal varices in cirrhotic patients, in addition to safety in […]
Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
This is a double-blind placebo controlled dose escalation trial evaluating efficacy and safety of inactivated rFVIIa (FFR-rFVIIa) as an antithrombotic agent. The trial showed a dose dependent prolongation of the […]
Hemostatic changes in patients receiving hydroxyethyl starch: The influence of ABO blood group.
This article is of interest in clinical decision-making related to starches usage. However, its interest is even higher for researchers in the field of volume replacement. – M. Mythen.